Status
Conditions
Treatments
About
This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.
Full description
Primary Study Objectives:
Determine if cryptic alterations exist within or near to the ALPL gene in patients with clinical diagnosis of hypophosphatasia, but without identifiable pathogenic or likely pathogenic variant on commercial testing.
Secondary Study Objective(s):
Characterize functional effects of variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia
Further characterize the differential diagnosis of hypophosphatasemia in patients with skeletal disease
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Aim 1-
Diagnosis of Hypophosphatasia based on clinical features that include
Lack of detection of a variant on molecular analysis of the ALPL gene. When possible, first degree relatives (parents, siblings, or child) will be included for the sole purpose of trio testing. No additional information will be collected on first degree relatives.
Aim 2-
Exclusion criteria
Aim 1-
Aim 2-
Loading...
Central trial contact
Eric Rush
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal